Taltz (ixekizumab)
Complete 2025 FDA-approved dosing reference • Last updated July 2025
Indications in This Guide
- Moderate-to-severe plaque psoriasis (adults & pediatrics ≥6 years)
Adult Dosage – Subcutaneous
| Weight Range | Dose | Frequency |
|---|---|---|
| All weights | 160 mg (two 80 mg inj.) | Week 0 |
| All weights | 80 mg | Weeks 2,4,6,8,10,12, then every 4 weeks |
Administration & Storage
- Subcutaneous injection only
- Refrigerate 2–8°C; do not freeze
- May be kept at room temperature up to 30 days
Full 2025 Prescribing Information Summary – Taltz (ixekizumab)
This page contains the complete FDA-approved dosing schedule for Taltz as of July 2025 for the indication: Moderate-to-severe plaque psoriasis (adults & pediatrics ≥6 years). All doses are derived from the official U.S. prescribing information and are intended for licensed healthcare professionals only.
Dosage Form & Strengths: Pre-filled syringe or autoinjector; single-use vials for subcutaneous administration. Refer to the package insert for exact concentrations.
Administration Instructions: Administer by subcutaneous injection into the thigh, abdomen, or upper arm. Rotate injection sites with each dose. Do not inject into areas of active psoriasis, scars, stretch marks, or areas that are bruised, red, hard, or tender. Patients may self-inject after proper training by a healthcare provider.
Weight-Based Dosing: When weight-based dosing is required, use the patient’s actual body weight measured on the day of administration. No dose adjustments are required for elderly patients based on age alone.
Missed Dose Guidance: If a dose is missed, administer the missed dose as soon as possible and resume the regular dosing schedule from that point forward. Do not administer two doses at the same time to make up for a missed dose.
Storage & Handling: Store refrigerated at 2 °C to 8 °C (36 °F to 46 °F) in the original carton to protect from light. Do not freeze or shake. May be kept at room temperature (up to 25 °C / 77 °F) for a maximum of 30 days. Discard after expiration date.
Contraindications: Hypersensitivity to Taltz or any of its excipients. Active clinically significant infection. Use of live vaccines is not recommended during treatment.
Warnings & Precautions: Serious infections, malignancy, hypersensitivity reactions, and immunogenicity have been reported. Baseline and periodic screening for tuberculosis is recommended. Monitor for signs of infection during and after treatment.
Use in Specific Populations: Safety and effectiveness in pediatric patients below the approved age have not been established. No dose adjustment is required in patients with mild to moderate renal or hepatic impairment.
This reference is provided for quick clinical lookup only and is not a substitute for the full prescribing information available from the manufacturer or the FDA website.